HK1050198A1 - New pyrimidine-2,4,6-trione derivatives, processesfor their production and pharmaceutical agents co ntaining these compounds. - Google Patents

New pyrimidine-2,4,6-trione derivatives, processesfor their production and pharmaceutical agents co ntaining these compounds.

Info

Publication number
HK1050198A1
HK1050198A1 HK03102405A HK03102405A HK1050198A1 HK 1050198 A1 HK1050198 A1 HK 1050198A1 HK 03102405 A HK03102405 A HK 03102405A HK 03102405 A HK03102405 A HK 03102405A HK 1050198 A1 HK1050198 A1 HK 1050198A1
Authority
HK
Hong Kong
Prior art keywords
processesfor
ntaining
compounds
production
pharmaceutical agents
Prior art date
Application number
HK03102405A
Other languages
English (en)
Inventor
Frank Grams
Hans-Willi Krell
Herbert Leinert
Ernesto Menta
Gerd Zimmermann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1050198A1 publication Critical patent/HK1050198A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK03102405A 1999-10-01 2003-04-03 New pyrimidine-2,4,6-trione derivatives, processesfor their production and pharmaceutical agents co ntaining these compounds. HK1050198A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99119506 1999-10-01
PCT/EP2000/009535 WO2001025217A1 (en) 1999-10-01 2000-09-29 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds

Publications (1)

Publication Number Publication Date
HK1050198A1 true HK1050198A1 (en) 2003-06-13

Family

ID=8239103

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102405A HK1050198A1 (en) 1999-10-01 2003-04-03 New pyrimidine-2,4,6-trione derivatives, processesfor their production and pharmaceutical agents co ntaining these compounds.

Country Status (29)

Country Link
US (1) US6498252B1 (tr)
EP (1) EP1226128B1 (tr)
JP (1) JP3848160B2 (tr)
KR (1) KR100459975B1 (tr)
CN (1) CN1157382C (tr)
AR (1) AR033651A1 (tr)
AT (1) ATE289595T1 (tr)
AU (1) AU768309B2 (tr)
BR (1) BR0014678A (tr)
CA (1) CA2385863C (tr)
CO (1) CO5210860A1 (tr)
CZ (1) CZ20021535A3 (tr)
DE (1) DE60018301T2 (tr)
ES (1) ES2235955T3 (tr)
HK (1) HK1050198A1 (tr)
HU (1) HUP0202832A3 (tr)
IL (1) IL148573A0 (tr)
MA (1) MA26823A1 (tr)
MX (1) MXPA02003192A (tr)
NO (1) NO20021380D0 (tr)
NZ (1) NZ517635A (tr)
PE (1) PE20010659A1 (tr)
PL (1) PL202680B1 (tr)
RU (1) RU2248971C2 (tr)
TR (1) TR200200858T2 (tr)
UY (1) UY26362A1 (tr)
WO (1) WO2001025217A1 (tr)
YU (1) YU22102A (tr)
ZA (1) ZA200201754B (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
US20070191404A1 (en) * 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones
AU2005230379B2 (en) * 2004-04-01 2010-07-22 Universite De Liege Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases
EP1632489A1 (en) * 2004-08-24 2006-03-08 University of Liege 5-(1,1'-Biphenyl)-4-yl-5-(4-(4-aminoacylphenyl)-piperazin)-1-yl-pyrimidine-2,4,6-trione derivatives, as inhibitors of zinc metallondopeptidases, their preparation and use.
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
RU2598607C1 (ru) * 2015-07-16 2016-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" (Астраханский государственный университет) Способ получения 5-гетарилметиленпиримидин-2,4,6-трионов

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1246743B (de) * 1965-01-12 1967-08-10 Dresden Arzneimittel Verfahren zur Herstellung von 5-Phenyl-5-piperidinobarbitursaeuren
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8726714D0 (en) 1987-11-14 1987-12-16 Beecham Group Plc Compounds
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
DE69108363T2 (de) 1990-12-03 1995-08-31 Celltech Ltd Peptidylderivate.
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
DK0874830T3 (da) 1995-12-08 2003-04-22 Agouron Pharma Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
PL202680B1 (pl) 2009-07-31
HUP0202832A3 (en) 2003-03-28
TR200200858T2 (tr) 2002-07-22
PL357385A1 (en) 2004-07-26
CO5210860A1 (es) 2002-10-30
CN1157382C (zh) 2004-07-14
YU22102A (sh) 2004-11-25
KR100459975B1 (ko) 2004-12-03
CA2385863A1 (en) 2001-04-12
AU768309B2 (en) 2003-12-04
RU2248971C2 (ru) 2005-03-27
JP2003511376A (ja) 2003-03-25
EP1226128A1 (en) 2002-07-31
AU7784900A (en) 2001-05-10
WO2001025217A1 (en) 2001-04-12
IL148573A0 (en) 2002-09-12
DE60018301D1 (de) 2005-03-31
CA2385863C (en) 2009-04-14
NZ517635A (en) 2003-11-28
AR033651A1 (es) 2004-01-07
JP3848160B2 (ja) 2006-11-22
MXPA02003192A (es) 2002-09-30
PE20010659A1 (es) 2001-06-20
ES2235955T3 (es) 2005-07-16
ZA200201754B (en) 2003-06-02
CN1374954A (zh) 2002-10-16
NO20021380L (no) 2002-03-20
UY26362A1 (es) 2001-04-30
US6498252B1 (en) 2002-12-24
BR0014678A (pt) 2002-07-23
HUP0202832A2 (hu) 2003-02-28
ATE289595T1 (de) 2005-03-15
EP1226128B1 (en) 2005-02-23
NO20021380D0 (no) 2002-03-20
KR20020039356A (ko) 2002-05-25
DE60018301T2 (de) 2006-04-06
MA26823A1 (fr) 2004-12-20
CZ20021535A3 (cs) 2002-11-13

Similar Documents

Publication Publication Date Title
HRP20020129A2 (en) Pyrimidine-2,4,6-trione metalloproteinase inhbitors
HUP0202795A3 (en) Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
HUP0104917A3 (en) Azepinoindole derivatives, the production and use thereof
HK1047743A1 (en) New use and novel n-azabicyclo-amide derivatives.
ZA200104196B (en) Azepinoindole derivatives, the production and use thereof.
HK1045650A1 (en) Pharmaceutical composition.
HUP0203190A3 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
HK1092804A1 (en) New quinazoline derivatives
MXPA02001508A (es) Derivados de arilmetil-carbonilamino-tiazol y sus usos como agentes antitumorales.
ZA985406B (en) Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical preparations containing these compounds.
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
HUP0203524A3 (en) 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity, their use and pharmaceutical compositions containing them
MXPA01008148A (es) Derivados de epotilona, metodo para su produccion y su uso farmaceutico.
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
AU3819200A (en) 2,4-diamino-pyrimidine derivatives
HK1050198A1 (en) New pyrimidine-2,4,6-trione derivatives, processesfor their production and pharmaceutical agents co ntaining these compounds.
HK1051003A1 (en) Ciclesonide-containing aqueous pharmaceutical composition.
ZA989571B (en) 2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use.
ZA200110454B (en) Pharmaceutical complex.
MXPA02005070A (es) 1-benzazepinas sustituidas y derivados de las mismas.
EP1234834A4 (en) 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT
ZA200001747B (en) 3-Amino-3-arylpropan-1-ol derivatives, their preparation and use.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080929